Supplementation of Eriocitrin in Intestinal Microbiota

Status Terminated

Clinical Trial Summary

Pre-diabetes is characterized by high plasma concentration of glucose and glycated hemoglobin and is the main risk factor for the development of type 2 diabetes. Several studies show that the intestinal microbiota is intimately linked to cardio-metabolic factors (type 2 diabetes, insulin resistance) when in situations of dysbiosis. Food is a key element for a healthy microbiota, focusing on the consumption of polyphenols that modulate the intestinal environment through its alteration and production of short chain fatty acids, and can thus be a way of reversing situations such as pre- diabetes and insulin resistance. The objective of the study will be to investigate whether chronic supplementation of eriocitrin alters the intestinal microbiota of pre-diabetic and insulin resistant individuals, reversing these situations. This will be done by supplementation of eriocitrin-containing capsules with different dosages in pre-diabetic and insulin resistant individuals. There will be 12 weeks of intervention, with faecal collections, anthropometric and dietary evaluation, and then will be made microbiological analysis to identify the intestinal microbiota and biochemical analysis before and after the intervention. For statistical analysis, normality and homogeneity test (Kolmogorov-Smirnov and Levine test respectively), T-test to compare baseline time between groups and repeated-measures ANOVA (two-way) were used to compare changes within and between groups.

Clinical Trial Description

Individuals of both sexes between 30 and 60 years of age who present fasting glycemia between 100 mg / dL (5,6 mmol / L) and 125 mg / dL (6,9 mmol / L) 50, or concentration of glycated hemoglobin between 5.7% (39 mmol / mole) and 6.4% (47 mmol / mole) 50, or glycemic concentrations in the oral glucose tolerance test between 140mg / dL (7.8 mmol / L) to 199mg / dL (11.0 mmol / L) 50. The study will also include insulin-resistant individuals: insulin above 25 uU / mL, or who present HOMA-IR score above 2.7.

Individuals using supplements (vitamins, bioflavonoids), pregnant women and those who practice intense physical exercise (> 10h / week) will be excluded from the study.

The primary endpoint will be alteration of the microbiota with possible improvement of the glycemic profile, leading to the reversal of pre-diabetes and insulin resistance. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03925909
Study type	Interventional
Source	São Paulo State University
Contact
Status	Terminated
Phase	N/A
Start date	May 1, 2019
Completion date	March 23, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05052918` - The Effect of Exercise and Metformin on Carotid Intima-media Thickness in Patients With Prediabetes	N/A
Completed	`NCT03714646` - Beta Glucan and Acetate Production	N/A
Completed	`NCT03377244` - Healthy Body Healthy Souls in the Marshallese Population	N/A
Completed	`NCT04427982` - Dance and Diabetes/Prediabetes Self-Management	N/A
Recruiting	`NCT05008276` - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed	`NCT03480022` - Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS	Phase 3
Withdrawn	`NCT05726409` - Mobile Application to Create Healthy Food Preparation Habits for Patients With Diabetes and Prediabetes	N/A
Completed	`NCT02834078` - Effect of BGG on Glucose Metabolism and Other Markers of Metabolic Syndrome	N/A
Completed	`NCT04902326` - Behavioral Economics and Self-Determination Theory to Change Diabetes Risk (BEST Change)	N/A
Recruiting	`NCT04168372` - Fructose: Substrate, Stimulus, or Both?	N/A
Completed	`NCT03272074` - Egg Consumption and Glycemic Control in Individuals With Pre- and Type II-diabetes	N/A
Not yet recruiting	`NCT05939349` - A Prescription for Health Equity: A Healthcare Provider-based Produce Prescription Program for People With Prediabetes and Type 2 Diabetes	N/A
Completed	`NCT04978376` - TRE With Physical Activity for Weight Management	N/A
Recruiting	`NCT03997656` - A Digital Therapy for Diabetes Prevention Among Overweight Adults in Terengganu, Malaysia	N/A
Recruiting	`NCT05166785` - BRInging the Diabetes Prevention Program to GEriatric Populations	N/A
Completed	`NCT01729078` - Dietary Interventions in Prediabetes	N/A
Completed	`NCT04507685` - Asian Indian Prediabetes Study	N/A
Completed	`NCT03292315` - Once Weekly GLP-1 in Persons With Spinal Cord Injury	Phase 4
Active, not recruiting	`NCT05353790` - Dietary Exchanges With Avocado and Mango in Pre-diabetes	N/A
Active, not recruiting	`NCT03804892` - Can Brisk Walking Combined With Ingestion of a Lipid-lowering Drug Improve Fat Metabolism in Muscle?	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.